The Federal Antimonopoly Service (FAS) has approved the maximum sale price for Covidolek at 2,916 rubles.
RIA News: The Federal Antimonopoly Service (FAS) of the Russian Federation has agreed to fix the maximum sale price of Covidolek used to treat COVID-19, a package of 40 tablets will cost 2,916 rubles, an official from the authority said.
The Federal Antimonopoly Service has approved the maximum sale price of Covidolek. The message says that a package of 40 tablets 200 mg each will cost 2,916 rubles.
The agency announced that the drug is included in the list of vital and essential drugs (VED). “The medication has antiviral effects and is used to treat COVID-19,” according to the agency.
In March 2021, the Ministry of Health of the Russian Federation approved the phase III of clinical research of Covidolek (favipiravir). The manufacturer is Nanolek. The clinical research is expended to be completed by December 31, 2022.